Video

Dr. Tagawa on 2 radiopharmaceuticals for prostate cancer with a proven survival advantage

In this video, Scott T. Tagawa, MD, MS, FACP, discusses the alpha emitter radium-223 dichloride (Xofigo) and the PSMA targeted therapy lutetium Lu 177 vipivotide tetraxetan (Pluvicto), 2 FDA-approved radiopharmaceutical therapies that have proven survival advantages for patients with prostate cancer. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

Related Videos
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.